Search

You searched for "Benign"

233 results found

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

8 November 2021 | | URO - Basic Science Research, URO - Urologic Oncology
Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

Quality Improvement – how to get involved?

1 November 2018 | | URO - Core Urology
The General Medical Council (GMC) requires all trainee doctors to carry out Quality Improvement (QI) as part of our annual appraisal process [1]. Exactly what QI projects are and how to get involved is less widely understood. Traditionally surgical trainees...

A time management guide for urologists

1 July 2016 | | URO - Andrology, URO - Basic Science Research, URO - Endourology & Stones, URO - Infection, URO - Neurourology, URO - Paediatric Urology, URO - Functional / Reconstructive Urology, URO - Technology, URO - Trauma & Emergency, URO - Urologic Oncology, URO - Uroradiology
Good time management is thought to not only reduce stress, but to improve personal efficiency, service delivery, clinical effectiveness and patient care. It was Benjamin Franklin in the 18th Century who originally made the link between success and the proper...

The role of an enhanced recovery protocol in patients undergoing robotic radical cystectomy

1 July 2014 | | URO - Urologic Oncology
Enhanced recovery after surgery (ERAS) protocols are patient pathways designed to reduce surgical stress and accelerate postoperative recovery. Uptake of such protocols in colorectal surgery in particular has been high, however ERAS protocols developed or utilised in urological surgery have...

Update on immunotherapy for non-muscle invasive transitional cell carcinoma of the bladder

7 January 2021 | | URO - Urologic Oncology
Patients with high-risk non-muscle invasive bladder cancer (NMIBC) that have failed Bacillus Calmette-Guérin (BCG) treatment are a difficult group to treat, and many may not be suitable for the preferred treatment option of radical cystectomy. Bladder-preserving treatments for BCG-unresponsive high-risk...